SCHEMBL25002347

SCHEMBL25002347

O=C(Nc1ccccc1)[C@H](I)Cn1nc2ccccc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.43
▸ MAPT P10636 5/20 0.43
▸ LMNA P02545 3/20 0.43
▸ GAA P10253 2/20 0.43
▸ ATM Q13315 2/20 0.43
▸ POLB P06746 1/20 0.42
▸ KMT2A Q03164 4/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ HPGD P15428 2/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NPC1 O15118 3/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ HSP90AA1 P07900 2/20 0.39
▸ PKM P14618 1/20 0.38
▸ NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22225772 1.00 ALDH1A1 (0.43) ALDH1A1MAPTLMNAGAAATM
SCHEMBL21466973 0.82 MME (0.51) ALDH1A1MAPTLMNAGAAATM
SCHEMBL22225773 0.82 MME (0.51) ALDH1A1MAPTLMNAGAAATM
SCHEMBL21008394 0.77 APAF1 (0.56) ALDH1A1MAPTLMNAGAAPOLB
SCHEMBL21008396 0.77 APAF1 (0.56) ALDH1A1MAPTLMNAGAAPOLB
SCHEMBL21008395 0.77 APAF1 (0.56) ALDH1A1MAPTLMNAGAAPOLB
SCHEMBL18965315 0.73 DNM1 (0.51) ALDH1A1MAPTLMNAGAAPOLB
SCHEMBL18964880 0.73 DNM1 (0.51) ALDH1A1MAPTLMNAGAAPOLB
SCHEMBL21466931 0.73 MEN1 (0.60) ALDH1A1MAPTLMNAGAAATM
SCHEMBL7927457 0.73 MEN1 (0.60) ALDH1A1MAPTLMNAGAAATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873282-B2 Selective androgen receptor degrader (SARD) ligands and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2024-01-16 — — US disclosed
US-11648234-B2 Selective androgen receptor degrader (SARD) ligands and methods of use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2023-05-16 — — US disclosed
US-20230041951-A1 SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF Oncternal Therapeutics, Inc. 2023-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230041951-A1 SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF AR, AHR, BRDT ALDH1A1 1784/4885MAPT 407/4885LMNA 553/4885
US-11648234-B2 Selective androgen receptor degrader (SARD) ligands and methods of use AR, BRCA1, FSHR ALDH1A1 1961/4885MAPT 269/4885LMNA 627/4885
US-11873282-B2 Selective androgen receptor degrader (SARD) ligands and methods of use thereof AR, AHR, BRDT ALDH1A1 1784/4885MAPT 407/4885LMNA 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback